Raiffeisen Bank International’s Adaptimmune Therapeutics ADAP Stock Holding History

Raiffeisen Bank International’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-907	Closed	-$124	–	811
2025 Q2	$218	Hold	907	–	–	﹤0.01%	586
2025 Q1	$181	Hold	907	–	–	﹤0.01%	603
2024 Q4	$520	Buy	+907	New	+$661	﹤0.01%	597

Other funds holding ADAP

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Raiffeisen Bank International's ADAP Position: Q3 2025 in Review

Raiffeisen Bank International sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 907 shares — an estimated $124 sold.

Raiffeisen Bank International first reported a position in ADAP in Q4 2024 and held it in 3 quarters. The position peaked at $520 in Q4 2024. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

Raiffeisen Bank International reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
Raiffeisen Bank International sold 907 Adaptimmune Therapeutics shares in Q3 2025, an estimated $124.
Raiffeisen Bank International first reported a position in Adaptimmune Therapeutics in Q4 2024 and held it in 3 quarters.
Raiffeisen Bank International's Adaptimmune Therapeutics position peaked at $520 in Q4 2024.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Raiffeisen Bank International's 13F filing for Q3 2025, filed 10 Nov 2025.